Literature DB >> 10390213

Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

J L Lopez-Ribot1, R K McAtee, S Perea, W R Kirkpatrick, M G Rinaldi, T F Patterson.   

Abstract

Mechanisms of resistance to azoles in Candida albicans, the main etiologic agent of oropharyngeal candidiasis (OPC), include alterations in the target enzyme (lanosterol demethylase) and increased efflux of drug. Previous studies on mechanisms of resistance have been limited by the fact that only a single isolate from each OPC episode was available for study. Multiple isolates from each OPC episode were evaluated with oral samples plated in CHROMagar Candida with and without fluconazole to maximize detection of resistant yeasts. A total of 101 isolates from each of three serial episodes of OPC from four different patients were evaluated. Decreasing geometric means of fluconazole MICs with serial episodes of infection were detected in the four patients. However, 8-fold or larger (up to 32-fold) differences in fluconazole MICs were detected within isolates recovered at the same time point in 7 of 12 episodes. Strain identity was analyzed by DNA typing techniques and indicated that isolates from each patient represented mainly isogenic strains, but differed among patients. A Northern blot technique was used to monitor expression of ERG11 (encoding lanosterol demethylase) and genes coding for efflux pumps. This analysis revealed that clinical isolates obtained from the same patient and episode were phenotypically heterogeneous in their patterns of expression of these genes involved in fluconazole resistance. These results demonstrate the complexity of the distribution of the molecular mechanisms of antifungal drug resistance and indicate that different subpopulations of yeasts may coexist at a given time in the same patient and may develop resistance through different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390213      PMCID: PMC89334     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains.

Authors:  J Löffler; S L Kelly; H Hebart; U Schumacher; C Lass-Flörl; H Einsele
Journal:  FEMS Microbiol Lett       Date:  1997-06-15       Impact factor: 2.742

2.  Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes.

Authors:  A Schoofs; F C Odds; R Colebunders; M Ieven; L Wouters; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

Review 4.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

5.  New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance.

Authors:  T J Walsh; M Kasai; A Francesconi; D Landsman; S J Chanock
Journal:  J Med Vet Mycol       Date:  1997 Mar-Apr

6.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

8.  Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.

Authors:  T C White; M A Pfaller; M G Rinaldi; J Smith; S W Redding
Journal:  Oral Dis       Date:  1997-05       Impact factor: 3.511

9.  Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient.

Authors:  T Takasuka; G G Baily; M Birch; M J Anderson; D Law; D W Denning
Journal:  J Infect       Date:  1998-01       Impact factor: 6.072

10.  Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Authors:  D Sanglard; F Ischer; L Koymans; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

View more
  26 in total

1.  Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.

Authors:  A Martinez; J Regadera; E Jimenez; I Santos; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 4.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

Review 6.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

7.  Comparative genotyping of Candida albicans bloodstream and nonbloodstream isolates at a polymorphic microsatellite locus.

Authors:  F Dalle; N Franco; J Lopez; O Vagner; D Caillot; P Chavanet; B Cuisenier; S Aho; S Lizard; A Bonnin
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

8.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Lipidomics and in vitro azole resistance in Candida albicans.

Authors:  Ashutosh Singh; Kaushal Kumar Mahto; Rajendra Prasad
Journal:  OMICS       Date:  2013-02

10.  Oral lactoferrin treatment of experimental oral candidiasis in mice.

Authors:  Natsuko Takakura; Hiroyuki Wakabayashi; Hiroko Ishibashi; Susumu Teraguchi; Yoshitaka Tamura; Hideyo Yamaguchi; Shigeru Abe
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.